New developments have emerged from the American immunotherapy company ImmunityBio. The Saudi Food and Drug Authority (SFDA) has granted accelerated approval for its Anktiva combination therapy with immune checkpoint inhibitors. This regimen will be used to treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed following standard treatment.

This marks the first global approval for Anktiva in this specific indication. It is also the first approval for Anktiva administered via subcutaneous injection. Compared to traditional administration methods, subcutaneous injection may offer greater convenience for lung cancer patients, potentially improving treatment adherence. For the challenging disease of metastatic non-small cell lung cancer, this new treatment option undoubtedly brings fresh hope to patients.

ImmunityBio has consistently focused on research and innovation in the field of immunotherapy. The approval of Anktiva, a significant achievement in its R&D pipeline, in Saudi Arabia represents a crucial milestone for the company. Looking ahead, as this therapy is further applied and promoted in clinical practice, it holds the potential to improve the condition and enhance the quality of life for more patients with metastatic non-small cell lung cancer.